Close Menu

NEW YORK (GenomeWeb) – Biocept said today that it has made a preferred provider agreement with Harle Group subsidiary HarlePhil Ventures to market and distribute the company's Target Selector liquid biopsy assays in the Republic of the Philippines. 

Under the terms of the agreement, Biocept will still perform all diagnostic testing in its San Diego-based CLIA lab. HarlePhil will be responsible for sales, marketing, and distribution, and for managing reimbursements in the Philippines.  Additional terms of the transaction were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

Dec
11
Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.